Thanks Eire, although I find your multiplier of 6 for the...

Thanks Eire, although I find your multiplier of 6 for the revenue of $18 million for ADAPT completely out of whack with reality considering if its met it would represent a real 'breakout' of growth for ADAPT and a 160% increase on the FY/CY 17 figure of $7.1 million.... Considering the high margin/recurring nature of the revenue I thought even my multiplier of 8 was very very low and unrealistic although I wanted to keep it realistic. Time, as always will tell. First we have to actually achieve the revenue target!

The rest of your post I thought was pretty good.

One amendment to my original post I'd like to make is with regards to my valuation of the TAVR division which I had at $100 million based on 5 patents pending and good progress made in animal models.... If WP were to sign a co-commercialisation deal with a global major the value I'd think more appropriate to that division would be $250 million.